MedTrace Logo

Antiplatelet and Anti-inflammatory Effects of Statins and Ezetimibe

NCT00474123 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2010-07-14

Study results available
· View outcomes & findings →

Summary

Among patients with stable coronary artery disease (CAD), it is not clear if the pleiotropic effects of cholesterol reduction differ between high-dose simvastatin alone and combined ezetimibe/simvastatin.

The investigators sought to compare the anti-inflammatory and anti-platelet effects of ezetimibe 10 mg / simvastatin 20 mg (E10/S20) to simvastatin 80 mg (S80).

Conditions

  • Stable Angina

Interventions

DRUG

Simvastatin 80 mg/day for 6 weeks

Simvastatin 80 mg/day, single dose, for 6 weeks.

DRUG

Ezetimibe 10 mg / Simvastatin 20 mg

Ezetimibe 10 mg / Simvastatin 20 mg Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • CARLOS V SERRANO, PHD · Heart Institute (InCor) HOSPITAL DAS CLINICAS DA FACULDADE DE MEDICINA DA UNIVERSIDADE DE SAO PAULO (HCFMUSP)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-01-31
Completion
2009-08-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00474123 on ClinicalTrials.gov